Dual Cathepsin L/JAK-IN-1, identified by its CAS number 2450279-41-9, is a chemical compound designed to inhibit both cathepsin L, a cysteine protease involved in various physiological processes, and Janus kinase (JAK), which plays a crucial role in cytokine signaling pathways. This dual inhibition is significant in therapeutic contexts, particularly for conditions like cancer and autoimmune diseases, where both proteolytic activity and JAK-mediated signaling contribute to disease progression. The compound typically exhibits a specific binding affinity for its targets, which can lead to alterations in cellular signaling and proteolytic activity. Its structure likely includes functional groups that facilitate interaction with the active sites of both cathepsin L and JAK, enhancing its efficacy as a dual inhibitor. Additionally, the pharmacokinetic properties, such as solubility, stability, and bioavailability, are critical for its potential therapeutic applications. Overall, Dual Cathepsin L/JAK-IN-1 represents a promising avenue for developing targeted therapies in complex disease states.

Dual Cathepsin L/JAK-IN-1

2450279-41-9: Dual Cathepsin L/JAK-IN-1, identified by its CAS number 2450279-41-9, is a chemical compound designed to inhibit both cathepsin L, a cysteine protease involved in various physiological processes, and Janus kinase (JAK), which plays a crucial role in cytokine signaling pathways. This dual inhibition is significant in therapeutic contexts, particularly for conditions like cancer and autoimmune diseases, where both proteolytic activity and JAK-mediated signaling contribute to disease progression. The compound typically exhibits a specific binding affinity for its targets, which can lead to alterations in cellular signaling and proteolytic activity. Its structure likely includes functional groups that facilitate interaction with the active sites of both cathepsin L and JAK, enhancing its efficacy as a dual inhibitor. Additionally, the pharmacokinetic properties, such as solubility, stability, and bioavailability, are critical for its potential therapeutic applications. Overall, Dual Cathepsin L/JAK-IN-1 represents a promising avenue for developing targeted therapies in complex disease states.

<p>DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).</p>

CAS 2450279-41-9

Dual Cathepsin L/JAK-IN-1

Dual Cathepsin L/JAK-IN-1

Ref: TM-T205041